News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Siemens Healthcare Diagnostics Gets Warning Letter Over Blood Sample Testing Device


6/7/2012 8:46:59 AM

Siemens Healthcare Diagnostics, part of Siemens (NYSE:SI), has received a warning letter from the U.S. Food and Drug Administration over allegedly changing without following proper protocol the design of an immunoassay device used to test blood and other biological liquids. The letter, addressed to its Tarrytown, New York office dated May 29, said the company violated good manufacturing practices over changes made to its AD VIA Centaur iPTH immunoassay. The regulator faulted the company on alleged procedural violations to ensure the design fit the requirements for the device’s intended use. The company was missing documents to demonstrate that formal documented reviews of the design were being conducted at the appropriate stages.

Read at News Release
Read at FDA


comments powered by Disqus
News Release
FDA
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES